What is Pharming Group N.V.'s Shariah compliance score?

Pharming Group N.V. (PHAR) has a Shariah compliance score of 63/100 (Grade: B, Acceptable). AAOIFI Standard No. 21 requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30%, (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%.

Does Pharming Group N.V. pass AAOIFI screening?

Pharming Group N.V. (PHAR) passes AAOIFI Shariah screening. AAOIFI Standard No. 21 requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30%, (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. PHAR's debt-to-market-cap is 17.0%.

How much purification is needed for Pharming Group N.V.?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the percentage and amount for Pharming Group N.V. (PHAR) using the latest financial data.

Where can I screen Pharming Group N.V. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Pharming Group N.V. (PHAR) and 8,200+ securities. US-listed stocks and ETFs are screened under AAOIFI Standard No. 21. Bursa Malaysia securities carry the Securities Commission Malaysia's official status. Coins are screened separately, under published scholarly opinion. The verdict is free, with no credit card or signup required for basic screening. The compliance grade, score, and debt ratio are free too; the full ratio breakdown is part of Pro.

PHARHalalB

Unlock full report, free

Compliance Status

Halal

Screened on Oct 14, 2026 · AAOIFI Standard 21

Acceptable

63Score

Is Pharming Group N.V. (PHAR) halal? Halal. Based on AAOIFI screening, Pharming Group N.V. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 63/100 (Grade: B).

Quote this verdict

HalalScreener rates Pharming Group N.V. (PHAR) Halal, 63/100, grade B under AAOIFI Standard 21, screened Oct 14, 2026. Source: https://halalscreener.app/en/stock/PHAR

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Within the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

17.0% of 30.0% limit

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

You can own PHAR

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened PHAR's prohibited income, but the exact share you would need to purify is part of Pro.

Card needed, nothing charged today

PHAR: Is Pharming Group N.V. Halal?

Pharming Group N.V.

NASDAQHealthcareNL

$9.36

Market Cap: 662.5M

Get an email if PHAR's halal status changes

We re-screen Pharming Group N.V. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Pharming Group N.V.

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Oct 14, 2026

Want to check the math yourself?

The verdict above is final and free. Pro members can verify every ratio behind it: interest-bearing deposits, prohibited income breakdown, and the full math.

Free for 7 days. Cancel anytime.

Card needed, nothing charged today

AI Compliance Insight

PRO

Institutional-grade Shariah analysis

Card needed, nothing charged today

See why PHAR is rated Halal with institutional-grade analysis

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

Compliance History

Halalnow
since Aug 2026
Doubtful
until the change above
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: FMP

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Know the day PHAR's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

Get Started Free Browse Screener

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Pharming Group N.V. (PHAR) halal to invest in?

Based on AAOIFI Standard 21 screening, Pharming Group N.V. (PHAR) is rated Halal with a compliance grade of B (Acceptable). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Pharming Group N.V. get a B compliance rating?

Pharming Group N.V. (PHAR) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 17.0% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Pharming Group N.V.'s Shariah verdict?

Pharming Group N.V.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Pharming Group N.V. re-screened for Shariah compliance?

Pharming Group N.V. (PHAR) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Oct 14, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.